Related Experiment Video
Updated: Aug 19, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
Somatic mutations of epidermal growth factor receptor in colorectal carcinoma
Hisashi Nagahara1, Koshi Mimori, Mitsuhiko Ohta
1Department of Surgery, Medical Institute of Bioregulation, Kyushu University, 4546 Tsurumihara, Beppu 874-0838, Japan.
Purpose:
Somatic mutations of the epidermal growth factor receptor (EGFR) gene may predict the sensitivity of non-small cell lung carcinoma to gefitinib. However, no mutations have been reported for colorectal carcinoma. We therefore analyzed EGFR mutations in colorectal adenocarcinomas by the combined use of laser microdissection and sequencing of genomic DNA.
Experimental Design:
We examined 11 representative colorectal adenocarcinoma cell lines and 33 clinical samples of colorectal carcinoma. In the clinical cases, we carefully dissected only carcinoma cells from frozen sections by laser microdissection. After DNA extraction and PCR, we examined EGFR mutations by sequencing genomic DNA.
Results:
None of 11 colorectal carcinoma cell lines exhibited somatic mutations, but 4 of 33 clinical tumors (12%) exhibited mutations in the EGFR kinase domain. This may be the first report of somatic mutations in colorectal adenocarcinoma.
Conclusions:
Our findings suggest that a distinct minority of colorectal adenocarcinomas exhibit somatic mutations of EGFR, and these tumors may be susceptible to gefitinib treatment.
Insights
Somatic mutations in the epidermal growth factor receptor (EGFR) gene were found in 12% of colorectal adenocarcinomas. These EGFR mutations suggest potential sensitivity to gefitinib treatment in a subset of patients.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Somatic mutations in the epidermal growth factor receptor (EGFR) gene are established biomarkers for gefitinib sensitivity in non-small cell lung carcinoma.
- EGFR mutations have not been previously reported in colorectal carcinoma.
Purpose of the Study:
- To investigate the presence and frequency of somatic mutations in the EGFR gene within colorectal adenocarcinomas.
- To explore the potential implications of EGFR mutations for targeted therapy with gefitinib in colorectal cancer.
Main Methods:
- Analysis of 11 colorectal adenocarcinoma cell lines and 33 clinical colorectal carcinoma samples.
- Utilized laser microdissection to isolate carcinoma cells from frozen tissue sections.
- Performed DNA extraction, PCR amplification, and sequencing of the EGFR gene to identify mutations.
Main Results:
- No somatic EGFR mutations were detected in any of the 11 colorectal carcinoma cell lines.
- Somatic mutations within the EGFR kinase domain were identified in 4 out of 33 (12%) clinical colorectal tumors.
- This represents a potential first report of somatic EGFR mutations in colorectal adenocarcinoma.
Conclusions:
- A small proportion of colorectal adenocarcinomas harbor somatic mutations in the EGFR gene.
- These EGFR-mutated colorectal tumors may represent a distinct subset susceptible to treatment with gefitinib.
Related Concept Videos
Mitogens and the Cell Cycle
Cancers Originate from Somatic Mutations in a Single Cell
The Ras Gene
Ras is a superfamily...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
